Bui Timothy T, Lagman Carlito, Chung Lawrance K, Tenn Stephen, Lee Percy, Chin Robert K, Kaprealian Tania, Yang Isaac
Department of Neurosurgery, University of California, Los Angeles, CA, USA.
Department of Radiation Oncology, University of California, Los Angeles, CA, USA.
Brain Tumor Res Treat. 2017 Apr;5(1):10-15. doi: 10.14791/btrt.2017.5.1.10. Epub 2017 Apr 30.
Central neurocytoma (CN) typically presents as an intraventricular mass causing obstructive hydrocephalus. The first line of treatment is surgical resection with adjuvant conventional radiotherapy. Stereotactic radiosurgery (SRS) was proposed as an alternative therapy for CN because of its lower risk profile. The objective of this systematic analysis is to assess the efficacy of SRS for CN. A systematic analysis for CN treated with SRS was conducted in PubMed. Baseline patient characteristics and outcomes data were extracted. Heterogeneity and publication bias were also assessed. Univariate and multivariate linear regressions were used to test for correlations to the primary outcome: local control (LC). The estimated cumulative rate of LC was 92.2% (95% confidence interval: 86.5-95.7%, <0.001). Mean follow-up time was 62.4 months (range 3-149 months). Heterogeneity and publication bias were insignificant. The univariate linear regression models for both mean tumor volume and mean dose were significantly correlated with improved LC (<0.001). Our data suggests that SRS may be an effective and safe therapy for CN. However, the rarity of CN still limits the efficacy of a quantitative analysis. Future multi-institutional, randomized trials of CN patients should be considered to further elucidate this therapy.
中枢神经细胞瘤（CN）通常表现为引起梗阻性脑积水的脑室内肿块。一线治疗方法是手术切除并辅以传统放疗。立体定向放射外科（SRS）因其较低的风险被提议作为CN的替代治疗方法。本系统分析的目的是评估SRS治疗CN的疗效。在PubMed上对接受SRS治疗的CN进行了系统分析。提取了患者的基线特征和结局数据。还评估了异质性和发表偏倚。使用单变量和多变量线性回归来检验与主要结局：局部控制（LC）的相关性。LC的估计累积率为92.2%（95%置信区间：86.5 - 95.7%，<0.001）。平均随访时间为62.4个月（范围3 - 149个月）。异质性和发表偏倚不显著。平均肿瘤体积和平均剂量的单变量线性回归模型均与改善的LC显著相关（<0.001）。我们的数据表明，SRS可能是一种治疗CN的有效且安全的方法。然而，CN的罕见性仍然限制了定量分析的疗效。未来应考虑针对CN患者开展多机构、随机试验，以进一步阐明这种治疗方法。
